½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1453732

¼¼°èÀÇ ¿©¼º °Ç°­ ½ÃÀå(2024-2034³â)

Women¢¥s Health Market Report 2024-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Visiongain | ÆäÀÌÁö Á¤º¸: ¿µ¹® 351 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¿©¼º °Ç°­ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö ¿¬Æò±Õ 4.6%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿©¼ºÀÇ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í:

¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¿©¼º °Ç°­ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÇ·áºñ ÁöÃâ Áõ°¡, ÀÇ·á ±â¼ú ¹ßÀü, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. »ý½Ä °Ç°­, ÀÓ»êºÎ °Ç°­, À¯¹æ °Ç°­, °»³â±â °ü¸®, ¼º °Ç°­ µî ¿©¼º ƯÀ¯ÀÇ °Ç°­ ¿ä±¸¸¦ ÃæÁ·½ÃÅ°´Â Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©¼º °Ç°­ ±³À° ¹× ¿ËÈ£ È°µ¿À» ÃËÁøÇÏ´Â À̴ϼÅƼºê´Â ¿©¼º ƯÀ¯ÀÇ °Ç°­ ¹®Á¦¿Í Á¶±â ¹ß°ß ¹× Á¶±â Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ ÀÌÇظ¦ ³ôÀÌ´Â µ¥ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿©¼º °Ç°­ ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, Àü ¼¼°è ¿©¼ºµé¿¡°Ô Çõ½Å°ú °Ç°­ °³¼±ÀÇ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ȯÀÚ Ä¡·áÀÇ ±â¼ú ¹ßÀü :

±â¼úÀÇ ¹ßÀüÀº ¿©¼º °Ç°­ ½ÃÀåÀÇ Æǵµ¸¦ ºü¸£°Ô º¯È­½ÃÅ°°í ÀÖÀ¸¸ç, Çõ½Å°ú ȯÀÚ Ä¡·áÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ÷´Ü Áø´Ü µµ±¸ºÎÅÍ ÃÖ÷´Ü Ä¡·á¹ý±îÁö, ÀÌ·¯ÇÑ ¹ßÀüÀº °Ç°­ »óŸ¦ Áø´Ü, °ü¸® ¹× Ä¡·áÇÏ´Â ¹æ½Ä¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖÀ¸¸ç, 3D À¯¹æÃÔ¿µ¼ú°ú MRI¿Í °°Àº ÷´Ü ¿µ»ó Áø´Ü ±â¼úÀº À¯¹æ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â Á¤È®µµ¸¦ ³ôÀÌ°í »ýÁ¸À²À» Çâ»ó½ÃÅ°¸ç ħ½ÀÀû ¼ö¼úÀÇ Çʿ伺À» °¨¼Ò½ÃÅ°°í ÀÖ½À´Ï´Ù. º¹°­°æ ¼ö¼ú ¹× ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀº Àڱ󻸷Áõ ¹× ÀڱñÙÁ¾°ú °°Àº ºÎÀΰú ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¸ð¹ÙÀÏ ¾Û, ¿þ¾î·¯ºí ±â±â, ¿ø°Ý ÀÇ·á Ç÷§Æû°ú °°Àº µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀº Æí¸®ÇÑ Á¤º¸ Á¢±Ù, ¸ð´ÏÅ͸µ µµ±¸, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ °¡»ó »ó´ã µîÀ» ÅëÇØ ¿©¼ºµéÀÌ ÀÚ½ÅÀÇ °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¿©¼º °Ç°­ °á°ú¸¦ °³¼±ÇÏ°í, ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϸç, ¿©¼º °Ç°­ ºÐ¾ßÀÇ Àü¹ÝÀûÀÎ Ä¡·áÀÇ ÁúÀ» Çâ»ó½ÃÅ°´Â µ¥ ÀÖ¾î Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

¼¼°è ¿©¼º °Ç°­(Women's Health) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀΰú ½ÃÀå ±âȸ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/Áö¿ªº° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇص帳´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃßÁø ¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • COVID-19ÀÇ ¿µÇ⠺м®
  • PorterÀÇ Five Forces ºÐ¼®
  • PEST ºÐ¼®

Á¦4Àå ¿©¼º °Ç°­ ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
  • ÇÇÀÓ¾à
  • Æó°æ ÈÄ °ñ´Ù°øÁõ
  • È£¸£¸ó¼º ºÒÀÓÁõ
  • Æó°æ
  • ´Ù³¶¼º ³­¼ÒÁõÈıº
  • Àڱ󻸷Áõ ¹× ÀڱñÙÁ¾
  • ±âŸ
    • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² : Áö¿ªº°

Á¦5Àå ¿©¼º °Ç°­ ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
    • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² : Áö¿ªº°

Á¦6Àå ¿©¼º °Ç°­ ½ÃÀå ºÐ¼® : ÀǾàÇ°º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
  • Xgeva
  • Prolia
  • Mirena
  • Nexplanon
  • Forteo
  • Nuvaring
  • Premarin
  • Lupron
  • Lo Loestrin
  • Orilissa/Oriahnn
  • ±âŸ
    • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² : Áö¿ªº°

Á¦7Àå ¿©¼º °Ç°­ ½ÃÀå ºÐ¼® : À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø
  • Á¦³×¸¯ ÀǾàÇ°
  • ºê·£µå ÀǾàÇ°
    • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² : Áö¿ªº°

Á¦8Àå ¿©¼º °Ç°­ ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø

Á¦9Àå ºÏ¹ÌÀÇ ¿©¼º °Ç°­ ½ÃÀå ºÐ¼®

Á¦10Àå À¯·´ÀÇ ¿©¼º °Ç°­ ½ÃÀå ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿©¼º °Ç°­ ½ÃÀå ºÐ¼®

Á¦12Àå ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¿©¼º °Ç°­ ½ÃÀå ºÐ¼®

Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿©¼º °Ç°­ ½ÃÀå ºÐ¼®

Á¦14Àå ±â¾÷ °³¿ä

  • °æÀï ±¸µµ
  • Àü·«Àû Àü¸Á : ¿ä¾à
  • Abbott Laboratories
  • Bayer AG
  • Caldera Medical Inc.
  • Cardinal Health
  • Carestream Health
  • Cooper Surgical Inc.
  • L. Hoffman-La Roche Ltd.
  • General Electric Healthcare
  • Hologic Inc.
  • koninklijke philips n.v
  • MedGyn Products Inc.
  • Medline Industries, Inc.
  • Prestige Consumer Healthcare Inc.
  • Siemens AG

Á¦15Àå °á·Ð ¹× Á¦¾È

  • VisiongainÀÇ °á·Ð
  • Âü¿© ±â¾÷À» À§ÇÑ Ãßõ »çÇ×
LSH 24.04.17

The global Women's Health market is estimated to grow at a CAGR of 4.6% by 2034

The Women's Health Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing awareness about women's health issues

The women's health market is experiencing significant growth due to increasing awareness about women's health issues. This growth is driven by various factors such as rising healthcare expenditures, advancements in medical technology, and a greater focus on preventive care. There is a growing demand for products and services addressing women's unique health needs, including reproductive health, maternal health, breast health, menopause management, and sexual health. Additionally, initiatives promoting women's health education and advocacy have contributed to a greater understanding of gender-specific health concerns and the importance of early detection and treatment. The women's health market is expected to continue expanding, offering opportunities for innovation and improved healthcare outcomes for women worldwide.

Technological advancements in patient care

Technological advancements are rapidly reshaping the landscape of the women's health market, ushering in a new era of innovation and improved patient care. From sophisticated diagnostic tools to cutting-edge treatment modalities, these advancements are revolutionizing the way women's health conditions are diagnosed, managed, and treated. Advanced imaging techniques, such as 3D mammography and MRI, offer greater accuracy in detecting breast cancer at its earliest stages, improving survival rates and reducing the need for invasive procedures. Minimally invasive surgical techniques, including laparoscopy and robotic-assisted surgery, are providing safer and more effective options for addressing gynaecological conditions like endometriosis and fibroids. Moreover, digital health solutions such as mobile apps, wearable devices, and telemedicine platforms are empowering women to take charge of their health by providing convenient access to information, monitoring tools, and virtual consultations with healthcare providers. These technological innovations hold immense promise for enhancing women's health outcomes, driving market growth, and advancing the overall quality of care in the field of women's health.

What Questions Should You Ask before Buying a Market Research Report?

How is the Women's Health Market evolving?

What is driving and restraining the Women's Health Market?

How will each Women's Health submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Women's Health submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Women's Health Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Women's Health projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Women's Health projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Women's Health Market?

Where is the Women's Health Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Women's Health Market today, and over the next 10 years:

Our 351-page report provides 125 tables and 186 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Women's Health Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Women's Health prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

By Application

Contraceptives

Postmenopausal osteoporosis

Hormonal infertility

Menopause

Polycystic Ovary Syndrome

Endometriosis and Uterine Fibroids

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Drugs

Prolia

Xgeva

Mirena

Nexplanon

Forteo

Nuvaring

Premarin

Lupron

Lo Loestrin

Orilissa/Oriahnn

Others

By Type

Generics

Branded

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Women's Health Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Abbott

Bayer AG

Caldera Medical

Cardinal Health

Carestream

Cooper Surgical Inc.

L. Hoffman-La Roche Ltd.

GE Healthcare

Hologic

Koninklijke Philips N.V

MedGyn Products

Medline Industries, Inc.

Prestige Consumer Healthcare, Inc.

Siemens AG

Overall world revenue for Women's Health Market, 2024 to 2034 in terms of value the market will surpass US$ 61.0 billion in 2034, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Women's Health Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Women's Health Market, 2024 to 2034 Market, with forecasts for material, design, type, delivery and application, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 16 key national markets - See forecasts for the Women's Health Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Women's Health Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Women's Health Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Women's Health Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Heightened Attention Towards Emerging Economies
      • 3.2.1.2 Escalated Innovation Targeting New Therapeutic Solutions
      • 3.2.1.3 Expanded Investments in Technology to Enhance Patient Satisfaction
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Elevated Pricing Poses a Constraint on Market Expansion
      • 3.2.2.2 Increased Collaboration for the Development of Advanced Healthcare Infrastructure
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Expansion of Preventative Care Services Tailored to Women's Unique Health Needs.
      • 3.2.3.2 Improving Digital Health Platforms to Enhance the Access to Healthcare Services for Women, Particularly in Underserved Areas.
      • 3.2.3.3 Technological Advancements in Reproductive Health Services, Including Family Planning, Fertility Management, and Maternal Care
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Women's Health Market Analysis by Application

  • 4.1 Key Findings
  • 4.2 Application Segment: Market Attractiveness Index
  • 4.3 Women's Health Market Size Estimation and Forecast by Application
  • 4.4 Contraceptives
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Postmenopausal Osteoporosis
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Hormonal Infertility
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Menopause
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Polycystic Ovary Syndrome
    • 4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)
  • 4.9 Endometriosis and Uterine Fibroids
    • 4.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.9.2 Market Share by Region, 2024 & 2034 (%)
  • 4.10 Others
    • 4.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.10.2 Market Share by Region, 2024 & 2034 (%)

5 Women's Health Market Analysis by Distribution Channel

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 5.4 Hospital Pharmacies
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Retail Pharmacies
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Online Pharmacies
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Women's Health Market Analysis by Drugs

  • 6.1 Key Findings
  • 6.2 Application Segment: Market Attractiveness Index
  • 6.3 Women's Health Market Size Estimation and Forecast by Drugs
  • 6.4 Xgeva
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Prolia
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Mirena
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Nexplanon
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8 Forteo
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)
  • 6.9 Nuvaring
    • 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.9.2 Market Share by Region, 2024 & 2034 (%)
  • 6.10 Premarin
    • 6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.10.2 Market Share by Region, 2024 & 2034 (%)
  • 6.11 Lupron
    • 6.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.11.2 Market Share by Region, 2024 & 2034 (%)
  • 6.12 Lo Loestrin
    • 6.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.12.2 Market Share by Region, 2024 & 2034 (%)
  • 6.13 Orilissa/Oriahnn
    • 6.13.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.13.2 Market Share by Region, 2024 & 2034 (%)
  • 6.14 Others
    • 6.14.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.14.2 Market Share by Region, 2024 & 2034 (%)

7 Women's Health Market Analysis by Type

  • 7.1 Key Findings
  • 7.2 Application Segment: Market Attractiveness Index
  • 7.3 Women's Health Market Size Estimation and Forecast by Type
  • 7.4 Generic
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Branded
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 Women's Health Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Women's Health Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Women's Health Market Attractiveness Index
  • 9.3 North America Women's Health Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 North America Women's Health Market Size Estimation and Forecast by Country
  • 9.5 North America Women's Health Market Size Estimation and Forecast by Application
  • 9.6 North America Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 9.7 North America Women's Health Market Size Estimation and Forecast by Drugs
  • 9.8 North America Women's Health Market Size Estimation and Forecast by Type
  • 9.9 U.S. Women's Health Market Analysis
  • 9.10 Canada Women's Health Market Analysis

10 Europe Women's Health Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Women's Health Market Attractiveness Index
  • 10.3 Europe Women's Health Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Europe Women's Health Market Size Estimation and Forecast by Country
  • 10.5 Europe Women's Health Market Size Estimation and Forecast by Application
  • 10.6 Europe Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 10.7 Europe Women's Health Market Size Estimation and Forecast by Drugs
  • 10.8 Europe Women's Health Market Size Estimation and Forecast by Type
  • 10.9 Germany Women's Health Market Analysis
  • 10.10 France Women's Health Market Analysis
  • 10.11 UK Women's Health Market Analysis
  • 10.12 Italy Women's Health Market Analysis
  • 10.13 Spain Women's Health Market Analysis
  • 10.14 Russia Women's Health Market Analysis
  • 10.15 Poland Women's Health Market Analysis
  • 10.16 Belgium Women's Health Market Analysis
  • 10.17 Rest of Europe Women's Health Market Analysis

11 Asia Pacific Women's Health Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Women's Health Market Attractiveness Index
  • 11.3 Asia Pacific Women's Health Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Asia Pacific Women's Health Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Women's Health Market Size Estimation and Forecast by Application
  • 11.6 Asia Pacific Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 11.7 Asia Pacific Women's Health Market Size Estimation and Forecast by Drugs
  • 11.8 Asia Pacific Women's Health Market Size Estimation and Forecast by Type
  • 11.9 Japan Women's Health Market Analysis
  • 11.10 China Women's Health Market Analysis
  • 11.11 India Women's Health Market Analysis
  • 11.12 Australia Women's Health Market Analysis
  • 11.13 South Korea Women's Health Market Analysis
  • 11.14 Singapore Women's Health Market Analysis
  • 11.15 Taiwan Women's Health Market Analysis
  • 11.16 Rest of Asia Pacific Women's Health Market Analysis

12 Latin America Women's Health Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Women's Health Market Attractiveness Index
  • 12.3 Latin America Women's Health Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Latin America Women's Health Market Size Estimation and Forecast by Country
  • 12.5 Latin America Women's Health Market Size Estimation and Forecast by Application
  • 12.6 Latin America Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 12.7 Latin America Women's Health Market Size Estimation and Forecast by Drugs
  • 12.8 Latin America Women's Health Market Size Estimation and Forecast by Type
  • 12.9 Brazil Women's Health Market Analysis
  • 12.10 Mexico Women's Health Market Analysis
  • 12.11 Argentina Women's Health Market Analysis
  • 12.12 Colombia Women's Health Market Analysis
  • 12.13 Rest of Latin America Women's Health Market Analysis

13 MEA Women's Health Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Women's Health Market Attractiveness Index
  • 13.3 MEA Women's Health Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 MEA Women's Health Market Size Estimation and Forecast by Country
  • 13.5 MEA Women's Health Market Size Estimation and Forecast by Application
  • 13.6 MEA Women's Health Market Size Estimation and Forecast by Distribution Channel
  • 13.7 MEA Women's Health Market Size Estimation and Forecast by Drugs
  • 13.8 MEA Women's Health Market Size Estimation and Forecast by Type
  • 13.9 GCC Women's Health Market Analysis
  • 13.10 South Africa Women's Health Market Analysis
  • 13.11 Rest of MEA Women's Health Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Summary of all Strategic Outlook
  • 14.3 Abbott Laboratories
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2022
      • 14.4.3.2 R&D, 2017-2022
      • 14.4.3.3 Regional Market Shares, 2022
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Caldera Medical Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 Cardinal Health
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2023
      • 14.6.3.2 Regional Market Shares, 2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Carestream Health
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 Cooper Surgical Inc.
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2017-2023
      • 14.8.3.2 R&D, 2017-2023
      • 14.8.3.3 Regional Market Shares, 2023
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 L. Hoffman-La Roche Ltd.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2017-2023
      • 14.9.3.2 R&D, 2017-2023
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 General Electric Healthcare
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 R&D, 2017-2022
      • 14.10.3.3 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Hologic Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 R&D, 2017-2023
      • 14.11.3.3 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 koninklijke philips n.v
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 MedGyn Products Inc.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
  • 14.14 Medline Industries, Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
  • 14.15 Prestige Consumer Healthcare Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2022
    • 14.15.4 Product Benchmarking
  • 14.16 Siemens AG
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2023
      • 14.16.3.2 R&D, 2017-2023
      • 14.16.3.3 Regional Market Shares, 2023
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦